Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INKT
INKT logo

INKT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mink Therapeutics Inc (INKT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
12.140
1 Day change
-0.57%
52 Week Range
76.000
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

INKT is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is mildly constructive in pre-market, but there is no strong proprietary buy signal, no recent news catalyst, no supportive financial detail, and insider selling is materially increasing. For an impatient investor who does not want to wait for an optimal entry, this is still not strong enough to justify an immediate buy. Best current stance: hold and wait for stronger confirmation or a better entry.

Technical Analysis

Pre-market price is 12.405, sitting above the pivot at 12.2 and below resistance at 13.102. MACD histogram is positive and expanding, which supports short-term upside momentum. RSI_6 at 59.714 is neutral-to-slightly bullish, not overbought. Moving averages are converging, suggesting the stock is near a decision point rather than in a confirmed trend. Overall, the chart is constructive but not decisive; upside appears possible toward 13.102 and 13.659 if momentum continues, but the setup is not strong enough to call it a high-conviction entry.

Positive Catalysts

  • ["Pre-market trading is above the pivot level, which is mildly supportive.", "MACD histogram is positive and expanding, indicating improving momentum.", "Similar candlestick pattern analysis suggests a positive short-term drift with estimated upside over the next day, week, and month.", "No negative news flow in the last week."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no clear event-driven catalyst.", "Insiders are selling, and selling activity has increased 432.67% over the last month.", "Hedge funds are neutral with no significant bullish accumulation trend.", "No valuation data is available to support a fundamental buy thesis.", "No recent congress trading data is available."]

Financial Performance

Financial snapshot data was unavailable due to an error, so the latest quarter financial performance cannot be assessed. No seasonal quarter details were provided.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street consensus shift to support a bullish or bearish view.

Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
Wall Street analysts forecast INKT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.210
sliders
Low
35
Averages
35
High
35
Current: 12.210
sliders
Low
35
Averages
35
High
35
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$35
AI Analysis
2025-08-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35
AI Analysis
2025-08-15
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded MiNK Therapeutics to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company's Phase 2 gastric cancer data later this year as a "significant catalyst" for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target.
H.C. Wainwright
Emily Bodnar
Buy
to
Neutral
downgrade
$35
2025-07-15
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$35
2025-07-15
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics to Neutral from Buy with a $35 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INKT
Unlock Now

People Also Watch